Storia in 3 fonti

MapLight dives despite positive data for schizophrenia drug

Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.

Raccontata da

biopharmadive.com

endpoints.news

benzinga.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo23 h fa

MapLight dives despite positive data for schizophrenia drug

MapLight's schizophrenia drug achieved 4.5-point PANSS gain; stock fell 66% as investors compared it to Bristol Myers' Cobenfy (8.4-9.6). MapLight's better profile—no fasting, 19.9% vs. 28% discontinuation—shows tolerability can offset efficacy gaps in drug competition.

originale

benzinga.com7 h fa

MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal - MapLight Therapeut

MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dose missed the primary endpoint.

Leggi questa versione →

Timeline cronologica

lunedì 27 luglio 2026·biopharmadive.com
MapLight dives despite positive data for schizophrenia drug
Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.
lunedì 27 luglio 2026·endpoints.news
MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 win
MapLight Therapeutics' $MPLT stock fell 60%+ after ML-007C-MA's once-daily regimen missed Phase 2 ZEPHYR trial's primary endpoint; twice-daily dose succeeded vs. placebo.

MapLight dives despite positive data for schizophrenia drug

MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal - MapLight Therapeut

Timeline cronologica

MapLight dives despite positive data for schizophrenia drug

MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 win

MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 win

MapLight’s schizophrenia drug dampens once-daily hopes despite Phase 2 win

MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal - MapLight Therapeut